Fc receptor but not complement binding is important in antibody protection against HIV

Ann J. Hessell, Lars Hangartner, Meredith Hunter, Carin E. G. Havenith, Frank J. Beurskens, Joost M. Bakker, Caroline M. S. Lanigan, Gary Landucci, Donald N. Forthal, Paul W. H. I. Parren, Preston A. Marx and Dennis R. Burton ()
Additional contact information
Ann J. Hessell: The Scripps Research Institute, La Jolla, California 92037, USA
Lars Hangartner: The Scripps Research Institute, La Jolla, California 92037, USA
Meredith Hunter: Tulane National Primate Research Center, Tulane University, Covington, Louisiana 70433, USA
Carin E. G. Havenith: Genmab
Frank J. Beurskens: Genmab
Joost M. Bakker: Genmab
Caroline M. S. Lanigan: The Scripps Research Institute, La Jolla, California 92037, USA
Gary Landucci: University of California, Irvine School of Medicine, Irvine, California 92697, USA
Donald N. Forthal: University of California, Irvine School of Medicine, Irvine, California 92697, USA
Paul W. H. I. Parren: Genmab
Preston A. Marx: Tulane National Primate Research Center, Tulane University, Covington, Louisiana 70433, USA
Dennis R. Burton: The Scripps Research Institute, La Jolla, California 92037, USA

Nature, 2007, vol. 449, issue 7158, 101-104

Abstract: Double-barrelled vaccines Many effective vaccines act by inducing neutralizing antibodies, and this approach is a top priority in work on HIV vaccines. But a new study suggests that anti-HIV antibodies are most effective when they act in two ways: through neutralization — killing the virus outright and blocking its entry into T cells — and by killing infected cells. The use of engineered versions of a neutralizing human antibody that protects against HIV in a monkey model shows that protection is dependent not only the antibody's neutralizing activity, but also on its interaction with Fc receptors on effector cells, which may act to reduce virus yield from infected cells. This work suggests that the best results might be achieved with vaccines that recruit both neutralizing antibodies and cell-mediated immunity via agents such as macrophages and cytokinins, rather than antibodies.

Date: 2007
References: Add references at CitEc
Citations: View citations in EconPapers (5)

Downloads: (external link)
https://www.nature.com/articles/nature06106 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:449:y:2007:i:7158:d:10.1038_nature06106

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature06106

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().